Cryptococcosis in solid organ transplant recipients: Current state of the science

Clinical Infectious Diseases

Volumn 47, Issue 10, 2008, Pages 1321-1327

  Singh, Nina ^a,e   Dromer, Francoise ^c   Perfect, John R ^b   Lortholary, Olivier ^c,d,f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b DUKE UNIVERSITY   (United States)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CALCINEURIN INHIBITOR; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; THYMOCYTE ANTIBODY; VORICONAZOLE;

BLOOD ANALYSIS; CEREBROSPINAL FLUID; CLINICAL FEATURE; CRYPTOCOCCOSIS; GENOTYPE; GRAFT REJECTION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MORTALITY; NEUROIMAGING; NONHUMAN; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; URINALYSIS;

CRYPTOCOCCOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTS;

EID: 54249083471     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592690     Document Type: Review

References (66)

1. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16:677-88.
2. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients: report of 9 cases and review of the literature. Medicine 1996; 75:142-56.
3. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18:44-69.
4. Fortun J, Martin-Davila P, Moreno S, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52:813-9.
5. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001; 71:910-3.
6. Dromer F, Mathoulin-Pélissier S, Fontanet A, Ronin O, Dupont B, Lortholary O; the French Cryptococcus Study Group. Epidemiology of HIV-associate cryptococcosis in France (1985-2001): comparison of the pre-and post-HAART eras. AIDS 2004; 18:555-62.
7. Silveira EP, Husain S, Kwak EJ, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transplant Infect Dis 2007; 9:22-7.
8. Shelburne SA, Darcourt J, White C Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:1045-52.
9. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F; the French Cryptococcosis Study Group. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19:1043-9.
10. Singh N, Lortholary O, Alexander BD, et al.; the Cryptococcal Collaborative Transplant Study Group. An "immune reconstitution syndrome"-like entity associated with Cryptococcus neoformans infections in organ transplant recipients. Clin Infect Dis 2005; 40:1756-61.
11. Lanternier F, Chandesris M, Poirée S, et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant 2007; 7:2826-8.
12. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999; 37:3204-9.
13. Haugen RK, Baker RD. The pulmonary lesions in cryptococcosis with special reference to subpleural nodules. Am J Clin Pathol 1954; 37:1381-90.
14. Saha DC, Goldman DL, Shao X, et al. Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin Vaccine Immunol 2007; 14:1550-4.
15. Kapoor A, Flenchner SM, O'Malley K, Paolone D, File TM Jr, Cutrona AF. Cryptococcal meningitis in renal transplant patients associated with environmental exposure. Transpl Infect Dis 1999; 1:213-7.
16. Neuville S, Dromer F, Morin O, Dupont B, Ronin O, Lortholary O; the French Cryptococcosis Study Group. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis 2003; 36:337-47.
17. Nosanchuk JD, Shoham S, Fries BC, Shapiro DS, Levitz SM, Casadevall A. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med 2000; 132:205-8.
18. Ooi HS, Chen BTM, Cheng HL, Khoo OT, Chan KT. Survival of a patient transplanted with a kidney infected with Cryptococcus neoformans. Transplantation 1971; 11:428-9.
19. Beyt BEJ, Waltman SR. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med 1978; 298:825-6.
20. Pappas PG, Kaufmann C, Alexander B, et al. Prospective surveillance of invasive fungal infections (IfIs) among organ transplant recipients (OTRs) in the US 2001-2006. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007.
21. Husain C, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7:375-381.
22. Vilchez R, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002; 2:575-80.
23. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis: a study in 111 cases. Ann Intern Med 1974; 80:176-81.
24. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690-9.
25. Baddley JW, Perfect JR, Oster RA, et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 2008 [Epub ahead of print].
26. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal DC-52 antibody. Clin Infect Dis 2007; 44:204-12.
27. Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003; 36:789-94.
28. McCarthy KM, Morgan J, Wannemuehler KA, et al. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 2006; 20:2199-206.
29. Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O; the French Cryptococcis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the Crypto A/D study. PloS Med 2007; 4:e21.
30. Lortholary O, Sitbon K, Dromer F; the French Cryptococcus Study Group. Evidence for HIV and Cryptococcus neoformans interactions on the pro- and antiinflammatory responses in blood during AIDS-associated cryptococcosis. Clin Microbiol Infect 2005; 11:296-300.
31. Singh N, Alexander BD, Lortholary O, et al.; the Cryptococcal Collaborative Transplant Study Group. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756-64.
32. Jarvis JN, Harrison TS. Pulmonary cryptococcosis. Semin Respir Crit Care Med 2008; 29:141-50.
33. Heitman J. The ongoing cryptococcosis outbreak in the Pacific Northwest - insight from molecular biology. In: Program and abstracts of the 45th Annual Meeting of the Infectious Diseases Society of America (San Diego). Alexandria, VA: Infectious Diseases Society of America, 2007.
34. MacDougall L, Kidd SE, Galanis E, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 2007; 13:42-50.
35. Jabbour N, Reyes J, Kusne S, Martin M, Fung J. Cryptococcal meningitis after liver transplantation. Transplantation 1996; 61:146-67.
36. Gorlach J, Fox DS, Cutler NS, Cox GM, Perfect JR, Heitman J. Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. EMBO J 2000; 19:1-12.
37. Blankenship JR, Singh N, Alexander BD, Heitman J. Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. J Clin Microbiol 2005; 43:464-7.
38. Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Cryptococcal meningitis: an analysis among 5521 consecutive organ transplant recipients. Transpl Infect Dis 2002; 4:183-8.
39. Singh N, Lortholary O, Dromer F, et al.; the Cryptococcal Collaborative Transplant Study Group. Central nervous system cryptococcosis in solid organ transplant recipients: prognostic implications of cryptococcal antigen assay and abnormal neuroimaging findings. Transplantation 2008; 86:647-51
40. Mueller NJ, Fishman JA. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature. Transpl Infect Dis 2003; 5:140-3.
41. Casadevall A. What is the latest approach to pulmonary cryptococcosis. J Respir Dis 2004; 25:188-99.
42. Gloster HM Jr, Swerlick RA, Solomon AR. Cryptococcal cellulitis in a diabetic kidney transplant patient. J Am Acad Dermatol 1994; 30:1025-6.
43. Horrevorts AM, Huysmans FTM, Koopman RJJ, Jacques F, Meis GM. Cellulitis as first clinical presentation of disseminated cryptococcosis in renal transplant recipients. Scand J Infect Dis 1994; 26:623-6.
44. Dromer F, Mathoulin S, Dupont B, Letenneur L, Ronin O. Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. Clin Infect Dis 1996; 23:91-6.
45. White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992; 165:960-2.
46. Singh N, Lortholary O, Dromer F, et al. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation 2008; 86:647-51.
47. Robinson PA, Bauer M, Leal MA, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999; 28:82-92.
48. Charlier C, Dromer F, Leveque C, et al.; the French Cryptococcosis Study Group. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PloS One 2008; 3:E1950.
49. Copp D, Godwin J, Kirby K, Limaye A. Clinical and radiologic factors associated with pulmonary nodule etiology in organ transplant recipients. Am J Transplant 2006; 6:2759-64.
50. Paterson DL, Singh N, Gayowski T, Marino IR. Pulmonary nodules in liver transplant recipients. Medicine 1998; 77:50-8.
51. Saag MS, Cloud GA, Graybill JR, et al., and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated Cryptococcal meningitis. Clin Infect Dis 1999; 28:291-6.
52. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O.Major role for amphotericin B flucytosine combination in severe cryptococcosis. PloS One 2008; 3:e2870.
53. Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection. Transplantation 2005; 80:1033-9.
54. Pitisuttithum P, Negromi R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745-55.
55. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for lesscommon, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122-31.
56. Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7:395-401.
57. Singh N, Lortholary O, Alexander BD, et al.; the Cryptococcal Collaborative Transplant Study Group. Allograft loss in renal transplant recipients with C. neoformans associated immune reconstitution syndrome. Transplantation 2005; 80:1131-3.
58. Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:1049-52.
59. D'Elios MM, Josien R, Manghetti M, et al. Predominant Th1 cell infiltration in acute rejection episodes of human kidney grafts. Kidney Int 1997; 51:1876-84.
60. Gras J, Cornet A, Latinne D, Reding R. Evidence that Th1/Th2 immune deviation impacts on early graft acceptance after pediatric liver transplantation: results of immunological monitoring in 40 children. Am J Transplant 2004; 4:444.
61. Ferraris JR, Tambutti ML, Cardoni RL, Prigoshin N. Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: changes in the immune responses. Transplantation 2004; 77:532-7.
62. Hodge S, Hodge G, Flower R, Han P. Methyl-prednisolone upregulates monocyte IL-10 production in stimulated whole blood. Scand J Immunol 1999; 49:548-53.
63. Ingram PR, Howman R, Leahy MF, Dyer JR. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis 2007; 44:e115-7.
64. Dilhuydy MS, Jouary T, Demeaux H, Ravaud A. Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia. Br J Haematol 2007; 137:490.
65. Singh N. Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses. Eur J Clin Microbiol Infect Dis 2008; 27:403-8.
66. Kontoyiannis DP, Lewis RE, Alexander BD, et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 2008; 52:735-8.